2GAGE B F, WATERMAN A D, SHANNON W, et al.Validationof clinical classification schemes for predicting stroke :results from the National Registry of Atrial Fibrillation[J]. J AmMed Assoc, 285(22): 2864-2870.
3PETERSEN P,BOYSEN G, GODTFREDSEN J, et al.Placebo - controlled,randomised trial of warfarin and aspirin forprevention of thromboembolic complications in chronic atrialfibrillation. The Copenhagen AFASAK study [ J]. Lancet, 1989,1(8631):175-179.
4PETERSEN P. Thromboembolic complications in atrialfibrillation [J]. Stroke,1990, 21 (1) : 4-13.
9CLAES N, BUNTINX F, VIJGEN J, et al. The Belgianimprovement study on oral anticoagulation therapy : a randomizedclinical trial [J ]. Eur Heart J,2005 ,26(20) : 2159-2165.
10WITT D M, SADLER M A,SHANAHAN R L,et al. Effect ofa Centralized Clinical Pharmacy Anticoagulation Service on theOutcomes of Anticoagulation Therapy [J]. Chest, 2005,127 (5):1515-1522.
8Go A S,Hylek E M,Phillips K A,et al.Prevalence of diagnosed atrial fibrillation in adults:national implications for rhythm management and stroke prevention:the An Ticoagulation and Risk Factors in Atrial Fibrillation(ATRIA)Study[J].JAMA,2001,285(18):2370-2375.
9Swedberg K,Olsson L G,Charlesworth A,et al.Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers:results from COMET[J].Eur Heart J,2005,26(13):1303-1308.
10Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation.Analysis of pooled data from five randomized controlled trials[J].Arch Intern Med,1994,154(13):1449-1457.
